Menopause

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

A new Gallup survey found 51% of women in the United States reported negative healthcare experiences.

A new study links earlier menopause age to faster cognitive decline and earlier Alzheimer diagnosis.

The FDA office of Women's Health and Center for Drug Evaluation and Research and hosting a public workshop with a focus on testosterone use in menopausal women.

"Although availability of certain products or brands may vary by pharmacy or location, estradiol transdermal patches remain available," stated the federal agency in an update.

A recap of the top stories from August 2026 in women's health.

Take a look back at some of the top FDA and pipeline news in women's health from August 2026.

Peptides are highly specific signaling molecules with a heterogeneous evidence base; clinical application in women's health is most established through metabolic pathways, according to Carrie Carda, MD, MMS, MHS.

Comprehensive, trend-based hormone testing grounded in patient history offers a more complete clinical picture than isolated screening—but no panel replaces the symptom conversation, says Carrie Carda, MD, MMS, MHS.

TMP-SMX was linked to higher UTI treatment failure vs. nitrofurantoin and fosfomycin in postmenopausal women.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

A new cohort study links estrogen-only MHT use to reduced Alzheimer disease pathology.

A new LifeStance survey finds many women are unaware that perimenopause can affect mental health.

Women with type 2 diabetes reported more and worse menopause symptoms, especially in the postmenopause stage.

AbCellera's ABCL635 met primary efficacy endpoints in a Phase 2 trial for moderate-to-severe hot flashes.

Semaglutide showed broad menstrual adverse event signals in a FAERS analysis of reproductive-aged patients.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

One in 3 US women aged 35 and older is unsure if they’re in perimenopause, driven by symptom confusion and care barriers.

A pilot trial found nicotinamide riboside and pterostilbene cut hot flashes, bloating, and poor sleep by 50% or more in 7 days.

The SELF-GYN1 trial found that at-home transvaginal ultrasonography met diagnostic quality standards in 96.2% of scans and was significantly preferred by participants over in-clinic imaging.

A 12-week randomized trial found a standardized saffron extract improved mood, self-esteem, and sleep outcomes in menopausal women vs placebo.

A cross-sectional study published in Menopause found that while overall symptom burden was higher in women with average-age menopause, psychological and urogenital symptom scores did not differ significantly.

Experts explain the role and safety of Bayer's elinzanetant to treat vasomotor symptoms since its approval in October 2025.

A reader-driven look at the 10 most-viewed articles on Contemporary OB/GYN from the first half of 2026, spanning FDA decisions, clinical research, and emerging treatments across menopause, contraception, endometriosis, and pelvic health.

A study published in Frontiers in Public Health and led by Mount Sinai researchers found that postmenopausal women in lower-income neighborhoods experienced up to 3.8 times greater bone mineral density loss from air pollution exposure than women in wealthier areas, based on data from 9041 participants in the Women's Health Initiative.